Objectives-To evaluate the changes in regional cerebral blood flow (rCBF) and memory performance in patients with age related cognitive decline (ARCD) who did and did not become demented during a follow up period. Methods-Twenty four patients with ARCD were recruited from an outpatient memory clinic, of whom 18 were followed up over a mean period of two years. Eighteen patients with mild to moderate probable Alzheimer's disease and 18 aged normal controls were followed up over a mean period of three years. Memory performance and rCBF were evaluated quantitatively at inclusion and during follow up, using single photon emission computed tomography with xenon-133 injection and three subtests of the Wechsler memory scale (logical memory, paired associated learning, and digit span). Results-Patients with ARCD showed decreased rCBF and memory performance at initial evaluation compared with controls.
decreased rCBF and memory performance at initial evaluation compared with controls. Five of them became demented during the follow up period, with further decline in memory and rCBF. At inclusion, the only feature that distinguished these five patients as a group from the remainder was a pronounced temporoparietal asymmetry. The 13 patients with ARCD who did not become demented still exhibited impaired memory and rCBF at follow up, but without any further decline and no increase in flow asymmetry. Conclusions-Apart from patients in the preclinical phase of Alzheimer's disease, the ARCD category includes nondemented patients who have brain dysfimction that may represent a distinct clinical entity.
(7 Neurol Neurosurg Psychiatry 1997;62:601-608) Keywords : age related cognitive decline; cerebral blood flow; memory; Alzheimer's disease; longitudinal study
Older people often complain of memory loss and a mild but objective cognitive impairment is commonly found in elderly subjects.'-3 The natural history of these age related cognitive deficits is not well known and different diagnostic categories have been proposed. These categories, whatever their name and the clinical criteria they are built on, include aged persons who are not demented and the mild memory or cognitive decline they show cannot be accounted for by any recognised medical or psychiatric condition. Given the importance of the very early detection of a dementing process,4 we need to improve our knowledge of the relation between the age related cognitive decline (ARCD), as termed in the DSM-IV,5 and normal aging on the one hand, and dementia such as Alzheimer's disease on the other. This is a particularly interesting issue as recent longitudinal studies indicate that the preclinical stage of Alzheimer's disease is characterised by changes in cognitive abilities that may predict the subsequent development of overt dementia. [6] [7] [8] Neuroimaging techniques have added valuable information to the clinical evaluation of Alzheimer's disease. Consistent patterns of regional cerebral blood flow (rCBF) or metabolic defects have been reported in PET or single photon emission computed tomography (SPECT) studies, although the sensitivity and specificity of the techniques in the early stage of the disease have not been clearly established.9-12 Quantitative MRI studies have also documented a decrease in volume of the medial temporal lobe structures in Alzheimer's disease,'314 and two studies in aged normal subjects have reported a positive relation between the performance on memory tests and the volume of the hippocampal formation. '5 16 Only recently has imaging technology been applied to the study of ARCD and variants. '7-'9 Although most authors agree that a follow up of the subjects will be necessary to clarify the relation between the anatomical or functional changes in the brain and ARCD, only cross sectional data have been reported so far.
In the present longitudinal study, we measured the rCBF and memory performance of patients with ARCD and compared their initial and follow up values with those of age matched controls and patients with probable Alzheimer's disease, distinguishing the patients with ARCD who became demented from those who did not.
Methods

SUBJECTS
The 24 patients in the ARCD group were selected from outpatients with memory complaints who were referred to the memory clinic of the Department of Neurology, University Hospital, Toulouse, over one year. They were examined by a neurologist, a psychiatrist, and a neuropsychologist trained in the evaluation of aged persons and the diagnosis of dementia. All of them were administered a physical and neurological examination, the short French version-21 of the McNair and Kahn cognitive difficulties scale (CDS),2' the mini mental state examination (MMSE),22 subtests of the Wechsler memory scale (WMS),23 and the Hamilton rating scale for depression. 24 Additional neuropsychological evaluations were performed each time a decline in the performance of other cognitive abilities, mainly language, reasoning, or planning of a complex action, was suspected. When indicated by the clinical evaluation, CT, MRI, and appropriate laboratory tests were also performed. The 24 patients in the ARCD group (1) had a decline in memory or another cognitive function in comparison with the standardised performance of an age and education matched subject (when education norms were lacking, a 10%-1 2% decline compared with the expected performance was considered as normal for those with eight years of education or less); (2) scored over 24 on the MMSE and over 36 on the CDS; (3) scored less than nine on the Hamilton depression scale; and (4) were free of any neurological, psychiatric, or medical disorder and of drug use that could induce cognitive deterioration, and were independent in all activities of daily living. These patients met the criteria defined by the Working Party of the International Psychogeriatric Association29 and could be included in the new diagnostic category of age related cognitive decline of the DSM IV.' The focus of clinical attention was a mild but objective memory or cognitive decline that could not be attributed to a specific mental or neurological disorder. None of the patients was demented at initial evaluation according to the DSM III-R26 criteria for dementia. Some of them met the criteria for age associated memory impairment (AAMI),27 the modified criteria for AAMI,28 or the International Classification of Diseases (ICD-10) criteria for mild cognitive impairment. 29 As none of these categories fitted the whole group and as none had a clear superiority, we considered the new ARCD category as the most appropriate.
For each of the patients in the ARCD group, we calculated an auditory verbal memory score (AVMS) by adding up the scores on the logical memory (immediate recall) and paired associate learning (easy and hard word pairs, immediate recall) subtests of the WMS. 23 The digit span (DS, forward and backward) was also administered. Regional cerebral blood flow (rCBF) was measured by SPECT according to the procedure described below. Eighteen of the 24 patients with ARCD were followed up and had the memory testing repeated using the same tests. The rCBF measurement was also repeated. We telephoned the family physicians of the six subjects who were lost to follow up. Their answers allowed us to consider that, three years after inclusion, none of the patients had become demented. Despite our efforts, we failed to follow up each of our patients on the planned regular basis of one examination a year during three years. When several examinations were available, the last one was used for the study. Thus eight patients were followed up after one year, seven after two years, and three after three years.
The 18 patients of the probable Alzheimer's disease group were selected from among patients followed up in the Department of Neurology, University Hospital, Toulouse, and who met the NINCDS-ADRDA criteria for probable Alzheimer's disease. In addition, they had to score between 10 and 23 on MMSE at initial evaluation, and to have been followed up for at least one year with a second rCBF examination. The memory scores (AVMS and DS) at initial examination were also available for the patients with probable Alzheimer's disease.
Eighteen age matched normal volunteers were included as controls. These volunteers were subjects of an ongoing longitudinal study on rCBF in normal elderly persons. They had a normal neurological examination, no history of cerebral vascular or psychiatric disease, and normal CT. They did not receive the MMSE but their memory evaluation included the three subtests of the WMS used for calculating the AVMS and DS. They were followed up for at least one year and had at least two memory and rCBF measurements.
Written informed consent was obtained from the normal volunteers and from the subjects of the ARCD group. The local ethics committee approved the study.
SPECT IMAGING OF RCBF
Regional cerebral blood flow was measured using SPECT (Tomomatic 64, Medimatic, Copenhagen, Denmark) and intravenous injection of xenon-133 (2200 MBq). Data were collected from three transverse slices simultaneously, each 2 cm thick, parallel, and centred at 1, 5, and 9 cm above the orbitomeatal plane. The in plane resolution was 1 7 cm.
The subject's head was positioned at the appropriate level and in the appropriate direction according to graduated external markers. Marks were also drawn on the skin of the subject's face, and photographs of the head and of the marks were used for correct repositioning of the head at subsequent SPECT. During the four minute data collection, the subjects were lying with their eyes closed in a quiet dimly lit room. Absolute rCBF values were then calculated from the reconstructed images according to a method described previously. 30 The rCBF data were then transferred to a MacIntosh microcomputer for image analysis.
For the present study, we only analysed the images of the midslice (orbitomeatal plane+5) because this encompassed a large part of the associative cortices commonly reported to show the earliest and the most demonstrative defects in Alzheimer's disease. Mean flow in the slice (ml/i 00 g/min) was first calculated by averaging all the pixels of the slice. Then, according to the visual analysis of the image and to data of an anatomical stereotaxis atlas,3" we drew one large region of interest (ROI) in the parietal and temporal cortices of each hemisphere. These two ROIs corresponded to the posterior regions of pronounced hypoperfusion in patients with Alzheimer's disease, and their delineation was based on the experience of one of us (PC) in the analysis of the rCBF images of more than 200 patients with probable Alzheimer's disease. The delineation was made blind to the diagnosis, but obviously, for most of the patients with probable Alzheimer's disease, little doubt existed as to the diagnostic category after their rCBF image had been studied. We then calculated a parietotemporal flow value in ml/100 g/min by averaging the pixels of the right and left ROIs. Because asymmetries between homologous association cortices have been reported in the early stages of probable Alzheimer's disease,10 we also calculated the difference between the left and right parietotemporal flows, which is reported here as the parietotemporal asymmetry (unsigned). The absolute value rather than the signed value of the difference was used to allow for an averaged estimate of the magnitude of the asymmetry. To reduce the influence of between patient variability, we calculated an index of relative, normalised perfusion of these posterior regions, the parietotemporal: mean flow ratio.
STATISTICAL ANALYSIS
The data were analysed using the StatView IV and SuperANOVA software (Abacus Concepts Inc, Berkeley, CA, USA). A multivariate analysis of covariance (MANCOVA) was applied to the memory scores and to the set of rCBF variables, with age and education as covariates for the initial values, and age, education, and duration of follow up as covariates for follow up values. When significant, the overall multivariate test (Wilk's lambda test) indicates that the groups are significantly different on the set of memory scores or flow variables. Univariate Table 2 Initial cerebral bloodflow in controls, patients with age related cognitive decline (ARCD), and patients with probable Alzheimer's disease (AD) Mean flow, parietotemporal flow, and asymmetry are in ml/lOOg/min. *Group effect: F5, = 7-3, P < 0-01; tgroup effect: F57 = 21-9, P < 0-001; tgroup effect: F57 = 3 1, NS; §group effect: F27 = 31, P < 0 001; Idiffers from controls (P < 0-05); differs from controls (P < 0 02) and from probable AD (P < 0-001); **differs from probable AD (p < 0-001).
ANCOVA by group was then applied to each variable of the sets, followed, when the omnibus F value was significant, by post hoc comparisons using Fisher *Group effect: F2 = 1-4, NS; tgroup effect: F, = 3 9, P < 0 05; (P < 0 05) and from ARCD-non-demented (P < 0 02).
tdiffers from controls dence of dementia. At the follow up examination, these five patients met the NINCDS-ADRDA criteria for probable Alzheimer's disease, with obvious deficits in several of the higher brain functions. *Differs from probable AD (P < 0 01); tdiffers from probable AD (P < 0 05); tdiffers from controls (P < 0 05) and from probable AD (P < 0-001); §differs from controls (P < 0-01) and from probable AD (P < 0 01); ¶differs from controls (P < 0-01) and from ARCD-nondemented (P < 0 05); differs from probable AD (P < 0 001); **differs from controls (P < 0 05) and from probable AD (P < 0-01).
there was no further decline in the memory performance of the ARCD non-demented group, their AVMS and DS remained lower than those of the controls at follow up. of the demented patients were lower than those of controls but none of the decreases reached significance. Strikingly, the decrease was even more pronounced in the nondemented group, in which it reached significance for the parietotemporal flow. These initial rCBF values allowed us to calculate the decline with time (difference between the two consecutive rCBF measurements) for the demented and non-demented patients with ARCD. The decline in the temporoparietal region tended to be more pronounced in the ARCD demented group (-6 ml/100 g/min) than in the ARCD non-demented group (-1 ml/100 g/min) but the difference was non-significant (P = 0-13). The two groups did not differ with regard to the set of flow variables (Wilk's lambda F',, = 1-6, NS), but the five patients who later developed dementia already showed a pronounced asymmetry not found in the patients who did not become demented ( 33 However, only cross sectional data have been reported so far, and the consistency over time of the cognitive impairment and of the anatomical or functional changes has not been assessed, especially after distinguishing the patients who became demented from those who did not. The results of the present study show that non-demented elderly patients with mild memory or cognitive impairment have decreased rCBF compared with aged normal controls. Some of the patients with ARCD (five of 18) developed dementia of the Alzheimer type over one to three years, with further decline in memory and rCBF. At initial screening, and before any sign of overt dementia, these patients only differed from the rest of those with ARCD in that they showed a more pronounced temporoparietal asymmetry, the predictive value of which cannot be established from such a small sample. The patients who were not demented after the follow up period still exhibited impaired memory and decreased rCBF compared with controls, but they did not show any further memory or rCBF decline compared with their initial levels. At follow up, these non-demented patients with ARCD had higher memory performance than the patients with ARCD who became demented, as well as higher memory and rCBF than the patients in the probable The few available longitudinal studies of elderly normal subjects and patients with ARCD generally agree on the stability of the age-related cognitive deficit over time and on the few patients in whom such a decline was prodromal to progressive dementia (for a review, see Caine3"). However, as in our study, the duration of follow up in these studies does not exceed four or five years. The recent studies by 
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